| Shanua Buck, | |
|
82 S 800 W, Brigham City, UT 84302-2400 | |
| (435) 723-8548 | |
| Not Available |
| Full Name | Shanua Buck |
|---|---|
| Gender | Female |
| Speciality | Counselor |
| Location | 82 S 800 W, Brigham City, Utah |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003119249 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101Y00000X | Counselor | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Shanua Buck, Po Box 526, Brigham City, UT 84302-0526 Ph: (435) 538-8144 | Shanua Buck, 82 S 800 W, Brigham City, UT 84302-2400 Ph: (435) 723-8548 |
News Archive
DARA BioSciences, Inc., a specialty pharmaceutical company focused on oncology and oncology supportive care products, announced today it has submitted an Orphan Drug Application to the U.S. Food and Drug Administration (FDA) for KRN5500, a compound in development to treat a painful form of chronic chemotherapy-induced peripheral neuropathy (CCIPN).
The Robert Wood Johnson Foundation is proud to announce today the recipients of its 2012 Community Health Leaders Award, honoring 10 individuals who have surmounted significant challenges to help improve health and health care in their communities.
A study by researchers from the schools of science and medicine at Indiana University-Purdue University Indianapolis examines the effects of carbon nanoparticles (CNPs) on living cells. This work is among the first to study concentrations of these tiny particles that are low enough to mimic the actual exposure of an ordinary individual.
National Institute of Standards and Technology researchers at the Institute for Bioscience and Biotechnology Research have demonstrated the most precise method yet to measure the structural configuration of monoclonal antibodies (mAbs), an important factor in determining the safety and efficacy of these biomolecules as medicines.
Scientists from Israel have recently explored the effectiveness of two-dose and three-dose regimens of the BNT162b2 coronavirus disease 2019 (COVID-19) vaccine (Pfizer/BioNTech) to reduce viral load in breakthrough infections caused by the delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
› Verified 6 days ago
Matthew Lamar Huff, Counselor Medicare: Not Enrolled in Medicare Practice Location: 82 S 800 W, Brigham City, UT 84302 Phone: 435-723-8548 Fax: 435-538-5066 | |
Alexandra Rosales, Counselor Medicare: Not Enrolled in Medicare Practice Location: 971 S 800 W, Brigham City, UT 84302 Phone: 435-239-8445 | |
Tein Daniel Hawke, Counselor Medicare: Not Enrolled in Medicare Practice Location: 862 S Main Suite 4, Brigham City, UT 84302 Phone: 435-723-1799 | |
Jesus Franco, Counselor Medicare: Not Enrolled in Medicare Practice Location: 82 S 800 W, Brigham City, UT 84302 Phone: 435-723-8548 | |
Esmeralda Gil, Counselor Medicare: Not Enrolled in Medicare Practice Location: 971 S 800 W, Brigham City, UT 84302 Phone: 435-239-8445 | |
William Miller I, Counselor Medicare: Not Enrolled in Medicare Practice Location: 862 S Main Suite 4, Brigham City, UT 84302 Phone: 435-723-1799 |